India pharma sector eyes 10% FY27 growth as domestic demand offsets US generics slowdown
India Ratings and Research expects India’s pharma sector to grow about 10% in FY27, supported by domestic demand, CDMO momentum and an API recovery despite softer US generics growth.
The development
India Ratings and Research forecast around 10% FY27 growth for the pharma sector, as domestic demand, CDMO activity and API recovery offset weakness in US generics.
The numbers
- 10%
- FY27
- 15.9%
- April-June 2026
- 18
Why it matters to operators and investors
India pharma’s projected 10% FY27 growth supports a resilient sector outlook, with domestic formulations, CDMO exposure and API recovery offering relative buffers against US generics pressure.
What to watch next
- Quarterly Indian Pharmaceutical Market domestic volume growth, especially chronic, cardiometabolic and anti-infective categories.
- US FDA approval cadence, warning letters, inspection outcomes and ANDA launch opportunities for major Indian exporters.
- US generic price indices, customer consolidation behavior and management commentary on channel inventory and tender pricing.
- CDMO order-book growth, utilization rates, client additions and announced capacity investments.
- API price trends, China supply conditions, import dependence and gross-margin guidance.
The counter-case
A 10% FY27 growth forecast may be vulnerable if domestic volume growth slows under price controls, competitive intensity rises in chronic therapies, or rural demand weakens. US generics could deteriorate more sharply than assumed due to persistent price erosion, delayed launches, FDA compliance issues, or a stronger rupee. CDMO growth may be uneven and concentrated among a few scaled players, while API recovery could be undermined by renewed Chinese price competition, input-cost volatility, and geopolitical supply disruptions.